Clinical Case: Treatment of a Giant Cells Tumor of the Proximal Femur in a Disadvantaged Area  

作　　者：M. Sawadogo S. Ouedraogo A. Korsaga S. Tinto A. J. I. Ouedraogo H. Kafando S. Ouedraogo M. Tall S. C. Da 

机构地区：[1]Ouahigouya Regional University Hospital Center, Ouahigouya, Burkina Faso [2]Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso

出　　处：《Open Journal of Orthopedics》2017年第11期362-368,共7页矫形学期刊（英文）

摘　　要：There have been not many reports on the result of intralesional excision for giant cell tumors (GCTs) of the great trochanter and femoral neck because of its rarity. The authors present the case of a 35-year-old female patient managed with intralesional curettage and filling the defect with autologous bone graft from iliac crest. An appoint of three doses of Denosumab was done postoperatively. The article discusses the clinical aspects and surgical treatment, and the benefits of Denosumab. This report aimed to demonstrate the possibility to perform curetage for giant cell tumor of the hip even the recommandation for this location is wide resection and endoprothesis fixation.There have been not many reports on the result of intralesional excision for giant cell tumors (GCTs) of the great trochanter and femoral neck because of its rarity. The authors present the case of a 35-year-old female patient managed with intralesional curettage and filling the defect with autologous bone graft from iliac crest. An appoint of three doses of Denosumab was done postoperatively. The article discusses the clinical aspects and surgical treatment, and the benefits of Denosumab. This report aimed to demonstrate the possibility to perform curetage for giant cell tumor of the hip even the recommandation for this location is wide resection and endoprothesis fixation.

关 键 词：GIANT Cell TUMOR FEMORAL NECK Great Trochanter CURETTAGE DENOSUMAB 

分 类 号：R73[医药卫生—肿瘤]